Core Viewpoint - The company announces the right for holders of "Huahai Convertible Bonds" to sell back part or all of their unconverted bonds, with a buyback price set at RMB 100.30 per bond, including accrued interest and tax [1][4]. Group 1: Buyback Terms - Holders of "Huahai Convertible Bonds" can exercise their right to sell back the bonds if the company's stock price remains below 70% of the conversion price for 30 consecutive trading days during the last two interest years of the bond [2]. - The buyback price is calculated to include accrued interest, which for the sixth year at a coupon rate of 2.00% results in a total buyback price of RMB 100.30 per bond [5][10]. - The buyback period is set from December 22, 2025, to December 26, 2025, with funds to be disbursed on December 31, 2025 [4][11]. Group 2: Buyback Process - The buyback is voluntary, allowing bondholders to choose whether to participate [6]. - Bondholders must submit their buyback requests through the Shanghai Stock Exchange trading system during the specified buyback period [7]. - If a buyback request is not successful on the first day, bondholders can continue to submit requests on subsequent days within the buyback period [8]. Group 3: Trading During Buyback Period - "Huahai Convertible Bonds" will continue to trade during the buyback period but will not allow conversion into shares [13]. - If the total face value of the bonds in circulation falls below RMB 30 million due to buybacks, trading will still continue until the end of the buyback period [13].

Core Viewpoint - Zhejiang Huahai Pharmaceutical Co., Ltd. experienced a significant stock price fluctuation, with a cumulative closing price deviation exceeding 20% over three consecutive trading days in late August and early September 2025 [2][8]. Group 1: Stock Trading Anomalies - The company's stock price deviation was identified as an abnormal trading fluctuation according to the Shanghai Stock Exchange trading rules [2][8]. - The stock price increased significantly on August 28, 29, and September 1, 2025, leading to the trading anomaly classification [2][8]. Group 2: Company Operations and Financial Performance - As of the announcement date, the company's production and operations were reported to be normal, with no significant changes in market conditions or industry policies [3]. - For the first half of 2025, the company reported a net profit attributable to shareholders of 409.49 million yuan, a decrease of approximately 45.30% compared to the same period last year [3]. - The net profit after deducting non-recurring gains and losses was 363.42 million yuan, reflecting a decline of about 52.48% year-on-year [3]. Group 3: Major Events and Information Disclosure - The company confirmed that there were no undisclosed major events or significant information that should have been disclosed, including major asset restructuring, share issuance, or significant business collaborations [4]. - No media reports or market rumors were identified that could significantly impact the company's stock price [5]. - During the period of stock price fluctuation, there were no reported stock trading activities by the company's directors, senior management, or controlling shareholders [6]. Group 4: Board of Directors' Statement - The board of directors confirmed that, apart from the disclosed matters, there were no undisclosed items that should have been reported according to the Shanghai Stock Exchange rules [11].

Core Viewpoint - The announcement indicates that Jianfeng Group's subsidiary, Zhejiang Jianfeng Pharmaceutical Co., Ltd., has received approval from the National Medical Products Administration for the marketing application of the chemical raw material drug Canagliflozin, which is a SGLT2 inhibitor used for improving blood sugar control in adults with type II diabetes [1]. Group 1 - Jianfeng Pharmaceutical has received the approval notice for Canagliflozin, with the notification number 2025YS00624 [1]. - Canagliflozin functions by blocking glucose reabsorption in the kidneys, leading to reduced blood sugar levels, and its efficacy is independent of β-cell function and insulin resistance [1]. - As of the date of the announcement, there are 28 companies listed with an "A" status on the CDE raw and auxiliary package registration information platform, including Jiangsu Hengrui Medicine Co., Ltd. and Zhejiang Huahai Pharmaceutical Co., Ltd. [1].

Core Viewpoint - Jianfeng Group's subsidiary, Zhejiang Jianfeng Pharmaceutical Co., Ltd., has received approval from the National Medical Products Administration for the marketing application of the chemical raw material drug, Empagliflozin, which is an SGLT2 inhibitor used as an adjunct treatment for blood sugar control in adult patients with type II diabetes [1] Group 1 - Empagliflozin functions by blocking the reabsorption of glucose in the kidneys, leading to the excretion of excess glucose and thereby lowering blood sugar levels [1] - The glucose-lowering effect of Empagliflozin does not depend on β-cell function and insulin resistance [1] - As of the announcement date, there are 28 companies listed on the CDE raw and auxiliary materials registration information platform with status "A," including Jiangsu Hengrui Medicine Co., Ltd. and Zhejiang Huahai Pharmaceutical Co., Ltd. [1]

浙商证券股份有限公司 关于浙江华海药业股份有限公司 差异化权益分派事项的核查意见 浙商证券股份有限公司（以下简称"保荐机构"）作为浙江华海药业股份有 限公司（以下简称"华海药业"或"公司"）向特定对象发行股票的保荐机构， 根据《中华人民共和国公司法》 《中华人民共和国证券法》 《上海证券交易所股票 上市规则》《上海证券交易所上市公司自律监管指引第7号——回购股份》《上海 证券交易所上市公司自律监管指南第2号——业务办理》之第五号《权益分派》 等规定，对华海药业本次差异化权益分派相关事项进行了审慎核查，并出具核查 意见如下： 一、本次差异化权益分派方案 公司分别于 2025 年 4 月 28 日、2025 年 5 月 23 日召开了第八届董事会第三 次会议、2024 年年度股东大会，会议审议通过《公司 2024 年度利润分配方案》 具体内容为："以实施权益分派股权登记日登记的总股本扣除公司回购专用证券 账户股份数后的股本为基数，向全体股东每 10 股派送现金红利 2.5 元（含税）。 公司通过回购专用证券账户所持有的本公司股份不参与本次利润分配。如在实施 权益分派股权登记日期前，因可转债转股、回购股份注销等致使 ...

Core Viewpoint - Zhejiang Huahai Pharmaceutical Co., Ltd. has received temporary approval from the U.S. FDA for its generic drug, Sitagliptin Metformin Tablets, which is a significant step towards entering the U.S. market for diabetes treatment [1][2]. Group 1: Drug Approval Details - The U.S. FDA has granted temporary approval for the ANDA (Abbreviated New Drug Application) of Sitagliptin Metformin Tablets, indicating that the drug has met all review requirements but is still under patent protection [1][2]. - The drug is primarily used for the treatment of type 2 diabetes and was originally developed by MSD SUB MERCK, first launched in the U.S. in March 2007 [1][4]. - The estimated sales for this drug in the U.S. market for 2024 is approximately $1.1 billion [1]. Group 2: Financial and Strategic Implications - The company has invested around 11.4 million RMB in the research and development of Sitagliptin Metformin Tablets for the U.S. market [2]. - The temporary approval is expected to enhance the company's product supply chain, diversify its product portfolio, and improve market competitiveness, positively impacting its expansion into the U.S. market [2].